I think the trial is simply to look at using AI to interpret radiology screening, already shown to be more effective than human interpretation for small tumours.
Better testing for metastasis still needs large scale trialling, but we live in hope |
New NHS AI Breast cancer trial to be started involving the latest testing methods
700 patients
Im certain AGL are involved with Nvidia backing route, already RNS AGL collaboration with Recursion.
It’s on all news channels this morning. |
 Vitec the same can be said of the opposite individuals who were promoting agl years ago at much higher prices . The fact it's risen from 8p to 16p whilst a good little rise is just a small part of the story here and if you have followed it for over 2 decades like I have then you would know it's not been a great success as an investment .
That said there are signs of things turning here finally but it is very early days and the recent illumia news is likely to be some time away before it generates meaningful income to agl .
For that to happen they will need to raise capital at least once more and the share price needs to continue to climb otherwise the dilution alone will cause it to stall or even fall depending on the prices they take place .
So whilst I understand some positivity and the good news with illumia ,hurdles still remain for now . The next one will be in the coming months to avoid the going concern qualification in the accounts in may/June . If the AZ deal and esai deals can get announced before it happens then there is a good chance the raise will be at a decent level at least . Without those though this could drift back .
Interesting to watch and I hope they finally do it but I'm not convinced yet knowing what I suspect is coming .
Something positive to hold onto after a rough few years so I get the hype . |
We don’t know who will be right. That’s the whole point. |
Oh sorry. You are right and I am wrong. |
“For a massive Pharma company to acknowledge AGL and stand "shoulder to shoulder" states "we believe in the technology and we are going to commercialise it"”
It is just an hour long webinar. That is why balanced views are needed here. That is a ridiculous statement to make. You must be very insecure not to be able to happily argue with adverse views. |
The BB's are littered with individuals that state they have no agenda, no shares in the company they write about and want to save foolish investors from destroying their capital. They spend a large part of their day posting messages telling people that they are right.
The other side of the coin is that there are many shareholders that stay out of the limelight, do not post or post infrequently and understand their investment.
It is true that AGL stands at 10% of its value post FDA but the story has now become compelling. For a massive Pharma company to acknowledge AGL and stand "shoulder to shoulder" states "we believe in the technology and we are going to commercialise it". This is not any old Pharma. They are world leaders in liquid biopsy.
This is what I want as a shareholder. We are in bed with a company that can propel AGL to far greater heights. What we are seeing at the moment is just the start. Feb 6th will be very interesting and I think it will result in AGL getting a lot more awareness and enquiries. Exciting times. |
I thought I would give you the benefit of the doubt but you truely do not have a grasp of business and what is going on here. |
Thought they'd smack this down big time this morning with the wider market mayhem.
Surprisingly resilient at the MO. |
Posters on LSE are working overtime on this share. |
Thiopia. If you are benchmarking against AZN…
Revenue $51b
Value $200b
So 400% of revenues
AGL revenue £3m
So £12m market cap
Gotta compare like with like! |
Well anyone waiting on the sidelines, now is the buying opportunity! |
I think we need to add a zero to AGL Market Cap just to allow for the fact they are playing with the Big Boys now
AGL - Mkt Cap £50m
ILMN - Mkt Cap $20Bn
AZN - Mkt Cap $200Bn
free stock charts from uk.advfn.com |
As agreed with Bones, re visit the subject at the start of the 2nd half. |
Yazx you were doing the same placing scream when this was 8p. I remember your FUD. Many quotes available |
Patt may have a point, there may be a fundraise coming later this year but if the share can keep this upwards trajectory hopefully it won't be too dilutive and also with the rapid progress being made it may be the last one.
Also everyone seems to have forgotten that they are nearly 3 years into a 5 year trial with an NHS teaching hospital for prostate cancer where the lead researcher hypothesised Parsortix could become the standard of care for patients.
If that is a success it may only be 4 or 5 years before that becomes reality |
If i were a holder? You're an idiot. Wasting your Sunday on here with no holding.Move on.Exciting news will develop next week with Illumina and my bet Astrazeneca will get more involved. Still holding out for an offer from them. |
radders
I would take what he says with a large pinch of salt
A couple of weeks ago he showed up suggesting people should buy into STX
He was ramping STX in October when it was 5p
Then came a 3p placing and it fell as low as 2.2p
PATT is not a serious person let alone investor
sent from my iPhone |
Totally agree Bermudashorts. PATT’s rather dismissive comment “it is just more theorising from colleagues…221; entirely misses the point. |
I fully agree. It is very exciting but remember that everybody said that Abbotts would buy AGL out as soon as FDA clearance was obtained. It is always soon to be oh so exciting. The bald facts are that unless this turns into £ or $ contract pretty soon the excitement will rapidly disappear just like all the previous ones have. But there is always a chance it is this time. Maybe! |
radders,
Just to add to your post, the main EACR conference is their Annual Congress which was held in Rotterdam last year. Illumina sponsored a symposium at that conference - 'More to see with liquid biopsy'.
You can download Illumina's flyer 'Highlights at EACR 2024' from the link below and you'll see that there was a joint session with Angle's Anne-Sophie Pailhes-Jimenez and Illumina's Dr Anna Babayan and Dr Vincent Stevens. So both companies jointly presenting. They also mention Angle's poster on the flyer.
Worth noting that 3 days ago Illumina's Dr Babayan posted the following on linkedin:-
'So excited about this study done by ANGLE!
A dual workflow for CTC and ctDNA molecular characterisation using the same workflow allows truly unbiased comparison of the two major liquid biopsy analytes without compromising insights. This was highly needed to further deepen our knowledge about compelemetarity of the two analytes and maximize information we get from liquid biopsy analyses. Congrats to the ANGLE team! '
Clearly a very close and collaborative relationship. |
PATT, in an earlier post, you described the Illumina analysis as “interesting but far from any commercial application. It is just more theorising from colleagues who have worked together on this for years”.
However, when it comes to the dual ctDNA/CTC analysis, the first RNS on this subject was released just over a year ago (January 4, 2024). The critical distinction with Wednesday’s announcement is that, for the first time, they have published results using an actual Illumina panel. Or, to quote from the RNS “a workflow using, for the first time, an end-to-end Illumina solution for analysis.” Previously, the data results released were based on a third-party panel from NuProbe.
This is significant because, as AN explained to me on the day of the AGM, “what Illumina would obviously prefer is to use their DNA panel on their sequencer, because then they would be getting all of the revenues, not just a significant part of the revenues.” Illumina has a clear commercial interest in supporting this dual analysis, and the RNS refers to the webinar as being the “first joint marketing initiative for ANGLE and Illumina.”
This undoubtedly represents a major milestone for the company, and I look forward to learning more details. |
Illumina could buy this lot with some loose change... |
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
Hot Features
Premium
